The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol.
Open Access
- 1 January 1983
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 15 (1) , 95-101
- https://doi.org/10.1111/j.1365-2125.1983.tb01470.x
Abstract
1 Canrenone, the major active metabolite of spironolactone, decreased [3H]-progesterone binding to isolated uterine cytosolic progesterone receptors. The inhibition was concentration-dependent. 2 Canrenone did not alter [3H]-oestradiol binding to isolated uterine cytosolic oestrogen receptors. 3 Canrenone inhibition of progesterone binding to isolated cytosolic receptors was strictly competitive: Kd (apparent dissociation constant for progesterone binding) was increased in a concentration-dependent manner by canrenone, whereas Bmax (maximal number of progesterone binding sites/mg cytosolic protein) was unaltered. There was marked cooperativity in progesterone binding at high canrenone and low progesterone concentrations. The implication is that canrenone alters the subunit interaction of the receptor protein. 4 Kd for progesterone was 3.2 × 10(-9)M. Ki (the inhibition constant for canrenone with respect to progesterone binding) was 300 × 10(-9)M. Reports in the literature suggest that, following spironolactone administration, canrenone may rise to concentrations sufficiently high to inhibit progesterone binding. This action may contribute to the effect of spironolactone in inducing menstrual disturbances in female patients.This publication has 30 references indexed in Scilit:
- INTERACTION OF SPIRONOLACTONE WITH OESTRADIOL RECEPTORS IN CYTOSOLJournal of Endocrinology, 1980
- SpironolactoneAmerican Heart Journal, 1978
- Spironolactone: Disposition, Metabolism, Pharmacodynamics, and BioavailabilityDrug Metabolism Reviews, 1978
- Screening for anti-hormones by receptor studiesJournal of Steroid Biochemistry, 1975
- Molecular modifications of anti-aldosterone compounds: Effects on affinity of spirolactones for renal aldosterone receptorsBiochemical Pharmacology, 1974
- In vitro binding of progesterone to receptors in the human endometrium and the myometriumBiochimica et Biophysica Acta (BBA) - Protein Structure, 1973
- Spironolactone Therapy and AmenorrheaJAMA, 1970
- Mode of spirolactone action: competitive inhibition of aldosterone binding to kidney mineralocorticoid receptorsBiochemical Pharmacology, 1968
- Spironolactone Therapy and GynecomastiaJAMA, 1965
- THE ALDOSTERONE BLOCKING EFFECTS OF SPIROLACTONESThe Japanese Journal of Pharmacology, 1962